加速 RA 和狼疮药物合作：网络站点 (UH2/UH3)-猫眼课题宝

加速 RA 和狼疮药物合作：网络站点 (UH2/UH3)

批准号：

9240807

负责人：

MICHELLE A PETRI

金额：

$11.95万

依托单位：

JOHNS HOPKINS UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2014

资助国家：

美国

项目状态：

已结题

起止时间：

2014-09-24 至 2016-05-31

来源：

https://reporter.nih.gov/project-details/9240807

关键词：

Address Affect American Area Atherosclerosis Biological Biological Markers Biological Process Cardiovascular system Cessation of life Characteristics Chronic Clinic Visits Clinical Clinical Data Collaborations Coupled Cutaneous Data Data Analyses Data Collection Databases Disease Epidemiology Flare Genes Health Immune System Diseases Institution Kidney Knowledge Lead Longitudinal Studies Lung Lupus Measures Medical Medicine Molecular Genetics Monitor Morbidity - disease rate Musculoskeletal Organ Pathogenesis Pathology Pathway interactions Patients Peer Review Phase Positioning Attribute Prevalence Prognostic Marker Protocols documentation Publications Quality of life Recruitment Activity Research Resources Sample Size Sampling Scheme Site Specimen Subgroup Systemic Lupus Erythematosus Technology Testing Therapeutic Time Urine Visit Work body system clinical research site cohort gastrointestinal genetic signature insight instrument laboratory experiment member mortality neuropsychiatry patient subsets phase 2 study prevent sample collection targeted treatment therapeutic development therapeutic target

项目摘要

项目成果

MICHELLE A PETRI的其他基金

相似基金

相关文献

中文摘要

翻译

描述（由申请人提供）：霍普金斯狼疮队列研究是一项纵向研究，包括2,300多名SLE患者，每3个月按方案随访一次。通过我们与不同机构的合作努力和伙伴关系，并通过提供患者样本，我们将帮助回答许多悬而未决的问题。确定肾脏进展的生物学途径可能导致靶向治疗。我们的合作伙伴关系还将有助于识别与SLE疾病活动或相关器官损伤相关的基因或基因特征，可以阐明病理发生的途径，并为正确的患者子集提供靶向治疗。此外，通过识别导致疾病爆发的途径，可以用于开发预防疾病爆发的治疗方法。

英文摘要

DESCRIPTION (provided by applicant): The Hopkins Lupus Cohort is a longitudinal study of over 2,300 SLE patients followed every 3 months by protocol. Through our collaborative effort and partnership with different institutions and by supplying patient samples, we will help answers many unanswered questions. Identifying the biological pathways of renal progression could result in targeted therapeutics. Our partnership would also help in identifying genes or gene signatures associated with SLE disease activity or related organ damage could elucidate the pathways by which pathology occurs and result in targeted treatments offered to the correct subset of patients. Also, by Identifying pathways that lead to flares in disease can be used to develop therapeutics to prevent flares.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文